SOURCE: Aldeyra Therapeutics

Aldeyra Therapeutics

June 01, 2016 16:01 ET

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter Overallotment Option

LEXINGTON, MA--(Marketwired - Jun 1, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,760,000 shares of its common stock, including 360,000 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The net proceeds of the offering, including the full exercise of the option, were approximately $12.6 million, after deducting the underwriting discounts and commissions and the other estimated offering expenses payable by Aldeyra.

Stifel acted as sole manager for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on September 1, 2015. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on May 27, 2016 and is available on the SEC's web site at Copies of the prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to: Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, NS2, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. NS2 has not been approved for sale in the U.S. or elsewhere.

Contact Information


    Corporate Contact:
    Stephen Tulipano
    Aldeyra Therapeutics, Inc.
    Tel: +1 781-761-4904 Ext. 205
    Email Contact

    Investor Contact:
    Chris Brinzey
    Westwicke Partners
    Tel: +1 339-970-2843
    Email Contact